Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06598722
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-03
Brief Title:
BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemialymphoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Efficacy and Safety of BCL-2 Inhibitors Combined with the HyperCVAD Regimen in the Treatment of Newly Diagnosed T-lymphoblastic Leukemia Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The experimental group included patients diagnosed with T-ALLLBL T-lymphoblastic leukemia lymphoma at initial diagnosis who received treatment with BCL-2 inhibitors combined with the Hyper CVAD regimen The control group consisted of patients diagnosed with T-ALLLBL from multiple centers for whom basic information disease information treatment details and efficacy data were collected Propensity score matching was conducted with historical data matching factors included age gender initial LDH levels and the presence or absence of a large mediastinal mass at diagnosis to compare the advantages and disadvantages of the experimental regimen with previous induction treatment protocols The primary endpoint was the complete remission CR rate after induction chemotherapy while secondary endpoints included duration of remission DOR progression-free survival PFS overall survival OS and the occurrence of adverse events This study aims to provide a more effective and safer treatment option for patients with T-LBL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None